News
OPTN
0.8942
-3.61%
-0.0335
OptiNose Falls To US$1.19, But Insiders Sold At Lower Price
OptiNose, Inc. Insiders sold US$184k worth of stock over the past year. The average selling price of US$1.46 is below the current share price. In the last year, the biggest insider sale was US$69k to the CEO of OptiNoses. Opti nose shares have fallen by 11% in the last week. But the company doesn't have any insider buying in the past 12 months. Insiders own 7.8% of optinose shares.
Simply Wall St · 3d ago
Weekly Report: what happened at OPTN last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at OPTN last week (0401-0405)?
Weekly Report · 04/08 09:13
Weekly Report: what happened at OPTN last week (0325-0329)?
Weekly Report · 04/01 09:13
Lake Street Remains a Buy on Optinose (OPTN)
TipRanks · 03/26 12:45
Weekly Report: what happened at OPTN last week (0318-0322)?
Weekly Report · 03/25 09:13
Institutional investors may adopt severe steps after OptiNose, Inc.'s (NASDAQ:OPTN) latest 13% drop adds to a year losses
Institutional investors own over 50% of OptiNose, Inc. (NASDAQ:OPTN) The top 7 shareholders of the company own 51% of the stock. The company has a high level of institutional ownership, but this could be due to the nature of the firm's business. The recent share price drop of 13% for Opti nose suggests the company is sensitive to its owners. Optinose is owned by a group of 55% of the company, and has a market capitalization of US$184m. It's important to look at the company's ownership of shares to see who really controls the company.
Simply Wall St · 03/23 14:03
Optinose Is Maintained at Buy by Lake Street
Dow Jones · 03/18 13:44
Optinose Price Target Raised to $4.00/Share From $3.00 by Lake Street
Dow Jones · 03/18 13:44
Lake Street Maintains Buy on OptiNose, Raises Price Target to $4
Benzinga · 03/18 13:34
Health Care Sector Update for 03/18/2024: FENC, OPTN, HLN, PFE, XLV, IBB
NASDAQ · 03/18 13:16
Lake Street Sticks to Their Buy Rating for Optinose (OPTN)
TipRanks · 03/18 12:45
Analysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)
TipRanks · 03/18 11:00
Optinose’s XHANCE Expands Market Reach with FDA Label Extension: A Comprehensive Analysis
TipRanks · 03/18 10:27
Weekly Report: what happened at OPTN last week (0311-0315)?
Weekly Report · 03/18 09:13
OptiNose granted FDA nod to expand labeling for sinusitis therapy
Healthcare OptiNose granted FDA nod to expand labeling for sinusitis therapy. Xhance, a drug-device combination, is indicated in the U.S. For chronic Sinusitis. Nearly 30M adults in the US suffer from the disease.
Seeking Alpha · 03/16 12:37
12 Health Care Stocks Moving In Friday's After-Market Session
Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. Aclarion and SCWorx stock rose by 10.39% and 7.55% respectively.
Benzinga · 03/15 21:33
OptiNose Inc: FDA Approval and Future Pediatric Study for XHANCE
TipRanks · 03/15 19:52
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis
FDA approves Xhance as a treatment for certain patients with chronic rhinosinusitis. About 30 million adults in the U.S. Suffer from chronic sinusitis, company says. The disease affects about 30 million people in the United States. Optinose says it's the first medication approved for treatment of adults without nasal polyps.
Dow Jones · 03/15 19:48
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Barchart · 03/15 14:34
More
Webull provides a variety of real-time OPTN stock news. You can receive the latest news about Optinose through multiple platforms. This information may help you make smarter investment decisions.
About OPTN
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.